Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point-of-care CD19 CAR T-cell therapy for B-lineage malignancies
NCT05648019Phase 2Recruiting
- Sponsor
- KK Women's and Children's Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), sponsored by KK Women's and Children's Hospital. Started Mar 2022; status: recruiting.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05648019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648019.